Therapeutic vaccination against human papilloma virus induced malignancies.
about
Engineering opportunities in cancer immunotherapyInterest of Tumor-Specific CD4 T Helper 1 Cells for Therapeutic Anticancer VaccineVIN usual type-from the past to the futureReflections upon human cancer immune responsiveness to T cell-based therapyTherapy of human papillomavirus-related diseaseHigh-risk human papillomavirus targets crossroads in immune signalingHPV16 synthetic long peptide (HPV16-SLP) vaccination therapy of patients with advanced or recurrent HPV16-induced gynecological carcinoma, a phase II trial.Influence of HIV/AIDS on Cervical Cancer: A Retrospective Study From Tanzania.Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia.Identification of novel epitopes from human papillomavirus type 18 E7 that can sensitize PBMCs of multiple HLA class I against human cervical cancer.CD40-mediated amplification of local immunity by epithelial cells is impaired by HPV.Recombinant HPV16 E7 assembled into particles induces an immune response and specific tumour protection administered without adjuvant in an animal modelThe interferon-related developmental regulator 1 is used by human papillomavirus to suppress NFκB activation.Amino-functionalized poly(L-lactide) lamellar single crystals as a valuable substrate for delivery of HPV16-E7 tumor antigen in vaccine development.Therapeutic Vaccine Strategies against Human Papillomavirus.The tumor area occupied by Tbet+ cells in deeply invading cervical cancer predicts clinical outcome.A road map to Translational Medicine in Qatar and a model for the world.GTL001, a bivalent therapeutic vaccine against human papillomavirus 16 and 18, induces antigen-specific CD8+ T cell responses leading to tumor regression.Targeting human papillomavirus genome replication for antiviral drug discoveryImmunotherapy of human papilloma virus induced diseaseIntralymphatic mRNA vaccine induces CD8 T-cell responses that inhibit the growth of mucosally located tumoursEnhancing cancer immunotherapy by intracellular delivery of cell-penetrating peptides and stimulation of pattern-recognition receptor signaling.Potential use of lymph node-derived HPV-specific T cells for adoptive cell therapy of cervical cancer.Identificaiton of Novel Immunogenic Human Papillomavirus Type 16 E7-Specific Epitopes Restricted to HLA-A*33;03 for Cervical Cancer Immunotherapy.Targeting immune response with therapeutic vaccines in premalignant lesions and cervical cancer: hope or reality from clinical studiesHPV disease transmission protection and control.Treatment failure in patients with HPV 16-induced vulvar intraepithelial neoplasia: understanding different clinical responses to immunotherapy.Human papillomavirus therapeutic vaccines: targeting viral antigens as immunotherapy for precancerous disease and cancer.The STEAP1(262-270) peptide encapsulated into PLGA microspheres elicits strong cytotoxic T cell immunity in HLA-A*0201 transgenic mice--A new approach to immunotherapy against prostate carcinoma.Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer.Expression, Polyubiquitination, and Therapeutic Potential of Recombinant E6E7 from HPV16 Antigens Fused to Ubiquitin.Human Papillomavirus Downregulates the Expression of IFITM1 and RIPK3 to Escape from IFNγ- and TNFα-Mediated Antiproliferative Effects and Necroptosis.Vaccination during myeloid cell depletion by cancer chemotherapy fosters robust T cell responses.Expression of coinhibitory receptors on T cells in the microenvironment of usual vulvar intraepithelial neoplasia is related to proinflammatory effector T cells and an increased recurrence-free survival.Intraepithelial macrophage infiltration is related to a high number of regulatory T cells and promotes a progressive course of HPV-induced vulvar neoplasia.Vicious viruses and vigilant vaccines: effects of linguistic agency assignment in health policy advocacy.The long-term immune response after HPV16 peptide vaccination in women with low-grade pre-malignant disorders of the uterine cervix: a placebo-controlled phase II study.[Cancers of the upper aerodigestive tract associated with human papillomavirus].Tumor-infiltrating CD14-positive myeloid cells and CD8-positive T-cells prolong survival in patients with cervical carcinoma.Therapeutic vaccines for high-risk HPV-associated diseases.
P2860
Q26776373-7FE0E737-93B6-48DF-BA2C-CAA697544702Q26782583-B1C35901-6CE5-4730-954D-5B1FD9352929Q26865303-970D301B-8C83-4960-87BF-4E3E5974BC7BQ27004674-50E09E04-0778-48D4-9A7A-10FF2967ACB2Q27007473-AA217165-5191-429F-9682-5C381970FC69Q28084802-56717C21-4FAD-4E40-9C0F-CBD5A9FDFC21Q30538743-56579711-3F14-495B-816F-17E0DEDD42B1Q33859557-5B01E374-8020-40FA-8737-F466E76ABEDAQ33917224-486BF6C9-D128-4E69-B712-807E8525BB43Q34091377-85CD2C9C-4673-42B2-89AB-D29874ADADACQ34488528-B39A16DB-E1DE-4441-8301-2B37ECFA5E68Q35061200-0739AF0E-CD19-460C-B4DC-4B56B14A5F9FQ35245080-66A14EA1-1E30-46AE-B826-46CB40C71ACFQ35605933-01027CD4-9EA6-471F-B4B4-50EA932DAFDFQ35826752-4652DEDA-C599-4421-93A6-63E05A993296Q36050315-BE3190F7-C754-4B11-92F8-DEE46A808D58Q36217887-20974788-F86D-4A86-86D8-48F0D87CD0F3Q36310924-835602F7-6FE2-4904-BCE2-1A9A4213C1EEQ36315302-82AA4610-C9CD-4F79-9D21-84B2F410BE22Q36541008-0CAA1985-F1AF-4E96-BBA1-D6F451C56032Q36638606-1D71B25A-FA3C-45B1-B6B5-4BE4FC25E297Q37139813-4B5A85B3-76B6-45DE-9405-3381D4202DF9Q37399278-6FA6DA00-A25C-4AA0-996D-DDDC6B0976EDQ37438391-CE1D577F-365B-4EC6-A104-9383E3A98458Q37494787-DAA4DC35-4A82-4792-822C-7340CCF79096Q37705703-79BB23AE-0873-431E-8884-8B8D2495761DQ38036688-F3DD9A8D-F9F2-4217-8119-38708D921F3BQ38089937-F76C81F8-6F89-483E-8FE8-0CF050C1518DQ40160897-DE008938-9488-472E-9AD9-8BF5E085E3FBQ40242985-82EB376A-8D0D-4F87-9E1E-11A43250A941Q40394482-E4AA1065-ADEF-4C94-82B2-38AB4F453D15Q40422515-5D939892-CE2B-46DA-B0BE-E535EDAD30F8Q40802250-A181346D-7A7C-4FA6-A9EC-5D571D226769Q41739849-4D066E26-8EB5-47E8-B835-BFE61F5B6622Q41739878-45A65BB8-6FDF-44FA-ACF0-16DC1953E995Q42248087-5A3137D1-F26E-4938-9E22-A002FD69DFEDQ42255546-CF55A916-9D45-417C-983A-EC3D08B2F0C3Q43843212-F834B309-1473-4EA5-9C01-A965034D8148Q44876069-43210A3B-4098-4C04-A0BB-8E9C3424A9A3Q47255618-FA21FE2E-D0A9-4AE6-9610-0FED93A1F37C
P2860
Therapeutic vaccination against human papilloma virus induced malignancies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Therapeutic vaccination against human papilloma virus induced malignancies.
@en
Therapeutic vaccination against human papilloma virus induced malignancies.
@nl
type
label
Therapeutic vaccination against human papilloma virus induced malignancies.
@en
Therapeutic vaccination against human papilloma virus induced malignancies.
@nl
prefLabel
Therapeutic vaccination against human papilloma virus induced malignancies.
@en
Therapeutic vaccination against human papilloma virus induced malignancies.
@nl
P1476
Therapeutic vaccination against human papilloma virus induced malignancies.
@en
P2093
Cornelis J M Melief
Sjoerd H van der Burg
P304
P356
10.1016/J.COI.2010.12.010
P577
2011-01-13T00:00:00Z